{"id":"NCT01218958","sponsor":"Alkermes, Inc.","briefTitle":"ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Medisorb® Naltrexone in Alcohol-Dependent Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-02","primaryCompletion":"2003-09","completion":"2003-09","firstPosted":"2010-10-13","resultsPosted":"2010-12-07","lastUpdate":"2017-07-11"},"enrollment":624,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Alcoholism"],"interventions":[{"type":"DRUG","name":"Medisorb naltrexone 190 mg","otherNames":["naltrexone for extended-release injectable suspension"]},{"type":"DRUG","name":"Medisorb naltrexone 380 mg","otherNames":["VIVITROL 380 mg","naltrexone for extended-release injectable suspension"]},{"type":"DRUG","name":"Placebo matching Medisorb naltrexone 190 mg","otherNames":[]},{"type":"DRUG","name":"Placebo matching Medisorb naltrexone 380 mg","otherNames":["Placebo matching VIVITROL 380 mg"]}],"arms":[{"label":"Medisorb naltrexone 190 mg","type":"EXPERIMENTAL"},{"label":"Medisorb naltrexone 380 mg","type":"EXPERIMENTAL"},{"label":"Placebo for Medisorb naltrexone 190 mg","type":"PLACEBO_COMPARATOR"},{"label":"Placebo for Medisorb naltrexone 380 mg","type":"PLACEBO_COMPARATOR"}],"summary":"This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study conducted in subjects diagnosed with alcohol dependence as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. (DSM-IV). Subjects were randomized (2:2:1:1) to receive intramuscular (IM) injections of Medisorb® naltrexone 190 mg, Medisorb naltrexone 380 mg, placebo for Medisorb naltrexone 190 mg, or placebo for Medisorb naltrexone 380 mg (VIVITROL®). Study drug was administered every 4 weeks for a total of 6 injections.","primaryOutcome":{"measure":"Percentage of Heavy Drinking Days Over the Treatment Period","timeFrame":"Baseline through Week 24 (168 days)","effectByArm":[{"arm":"Medisorb Naltrexone 190 mg","deltaMin":14.75,"sd":null},{"arm":"Medisorb Naltrexone 380 mg","deltaMin":10.23,"sd":null},{"arm":"Placebo Groups (Pooled)","deltaMin":19.77,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"0.0245"},{"comp":"OG000 vs OG002","p":"0.0744"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["15811981","17873686","17588491","18241321","18348601","19053979","18775624","21769033","21575016"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":210},"commonTop":["Nausea","Headache NOS","Fatigue","Insomnia","Nasopharyngitis"]}}